These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 21054587)
1. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease. Epps KC; Wilensky RL J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587 [TBL] [Abstract][Full Text] [Related]
2. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
3. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Corson MA; Jones PH; Davidson MH Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871 [TBL] [Abstract][Full Text] [Related]
4. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?]. Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606 [TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Anderson JL Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868 [TBL] [Abstract][Full Text] [Related]
6. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2 and risk of stroke. Gorelick PB Am J Cardiol; 2008 Jun; 101(12A):34F-40F. PubMed ID: 18549870 [TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. Toth PP; McCullough PA; Wegner MS; Colley KJ Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. Rallidis LS; Tellis CC; Lekakis J; Rizos I; Varounis C; Charalampopoulos A; Zolindaki M; Dagres N; Anastasiou-Nana M; Tselepis AD J Am Coll Cardiol; 2012 Nov; 60(20):2053-60. PubMed ID: 23083783 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Lerman A; McConnell JP Am J Cardiol; 2008 Jun; 101(12A):11F-22F. PubMed ID: 18549867 [TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J; Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Khakpour H; Frishman WH Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473 [TBL] [Abstract][Full Text] [Related]
17. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022 [TBL] [Abstract][Full Text] [Related]
18. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676 [TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Oldgren J; James SK; Siegbahn A; Wallentin L Eur Heart J; 2007 Mar; 28(6):699-704. PubMed ID: 17314110 [TBL] [Abstract][Full Text] [Related]
20. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. Noto H; Chitkara P; Raskin P J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]